2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Phase 2
1
Status
Unknown
2
Completed
1
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Conditions
Vomiting
6
Postoperative Nausea and Vomiting
3
Neoplasms
3
Prostatic Neoplasms
1
Pain, Postoperative
1
Ovarian Neoplasms
1
Nausea
1
Myofibroma
1
Lung Neoplasms
1
Hematologic Neoplasms
1
Colonic Neoplasms
1
Agnosia
1
Adenomyosis
1
Interventions
pembrolizumab
185
Gemcitabine
170
Paclitaxel
152
Carboplatin
137
Bevacizumab
128
Surveys and Questionnaires
118
Cisplatin
115
Docetaxel
114
Blood Specimen Collection
110
Cyclophosphamide
109
Exercise
108
Nivolumab
98
Fluorouracil
90
Capecitabine
86
Dexamethasone
81
Radiotherapy
80
Irinotecan
74
Standard of Care
69
Pemetrexed
68
Oxaliplatin
68
Leucovorin
64
Drug Therapy
64
Cetuximab
60
Erlotinib Hydrochloride
56
Sorafenib
53
atezolizumab
52
Ipilimumab
51
Doxorubicin
50
trametinib
47
Interviews as Topic
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Neoplasms
×
ramosetron
×
Clear all
NCT02532634
2018-05-11
RAPA
Kangdong Sacred Heart Hospital
Phase 4
Completed
292 enrolled
NCT01536691
2012-10-03
ROAD
Hallym University Medical Center
Phase 3
Unknown
338 enrolled
NCT01046461
2012-02-17
RAD
Hallym University Medical Center
Phase 2
Unknown
41 enrolled